ATE370228T1 - Zur therapie und prophylaxe bakterieller infektionen geeignete bakteriophagen - Google Patents

Zur therapie und prophylaxe bakterieller infektionen geeignete bakteriophagen

Info

Publication number
ATE370228T1
ATE370228T1 AT03744903T AT03744903T ATE370228T1 AT E370228 T1 ATE370228 T1 AT E370228T1 AT 03744903 T AT03744903 T AT 03744903T AT 03744903 T AT03744903 T AT 03744903T AT E370228 T1 ATE370228 T1 AT E370228T1
Authority
AT
Austria
Prior art keywords
bacteriophages
bacterium
lysing
infecting
bacteria
Prior art date
Application number
AT03744903T
Other languages
English (en)
Inventor
Mark Rapson
Faith Burden
Liudmilla Glancey
David Hodgson
Nicholas Mann
Original Assignee
Univ Warwick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0207021.7A external-priority patent/GB0207021D0/en
Application filed by Univ Warwick filed Critical Univ Warwick
Application granted granted Critical
Publication of ATE370228T1 publication Critical patent/ATE370228T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1075—Isolating an individual clone by screening libraries by coupling phenotype to genotype, not provided for in other groups of this subclass
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT03744903T 2002-03-25 2003-03-19 Zur therapie und prophylaxe bakterieller infektionen geeignete bakteriophagen ATE370228T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0207021.7A GB0207021D0 (en) 2002-03-25 2002-03-25 Anti-bacterial agents
US10/215,056 US20030180319A1 (en) 2002-03-23 2002-08-07 Antibacterial agents

Publications (1)

Publication Number Publication Date
ATE370228T1 true ATE370228T1 (de) 2007-09-15

Family

ID=28456031

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03744903T ATE370228T1 (de) 2002-03-25 2003-03-19 Zur therapie und prophylaxe bakterieller infektionen geeignete bakteriophagen

Country Status (10)

Country Link
EP (1) EP1504088B1 (de)
JP (1) JP2005520545A (de)
CN (1) CN1643139A (de)
AT (1) ATE370228T1 (de)
AU (1) AU2003226499A1 (de)
CA (1) CA2479897A1 (de)
DE (1) DE60315636T2 (de)
DK (1) DK1504088T3 (de)
ES (1) ES2292996T3 (de)
WO (1) WO2003080823A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1677834B1 (de) * 2003-10-06 2014-01-08 Gangagen, Inc. Therapeutischer phage mit definierter dosis
US20060153811A1 (en) * 2005-01-10 2006-07-13 Jackson Lee E Use of viruses and virus-resistant microorganisms for controlling microorganism populations
CA2614800C (en) * 2005-07-12 2018-10-30 Micreos B.V. Bacteriophage specifically for lysing propionibacterium acnes and uses thereof
EP2004800B1 (de) * 2006-04-04 2014-01-15 Henry Morris Krisch Verfahren zur herstellung von bakteriophagenzusammensetzungen sowie verfahren auf dem gebiet der phagentherapie
JP2011501740A (ja) * 2007-10-04 2011-01-13 ノボリティクス・リミテッド 抗細菌組成物
GB0800149D0 (en) * 2008-01-04 2008-02-13 Novolytics Ltd Improved host range phage
CA2729160C (en) * 2008-07-03 2017-11-14 The Rockefeller University A chimeric bacteriophage lysin with activity against staphylococci bacteria
GB2466177A (en) * 2008-12-03 2010-06-16 Arab Science & Technology Found Bacteriophage selection and breeding
EP3115054B1 (de) * 2009-02-06 2019-11-20 Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA Antibakterielle phage, phagenpeptide und verfahren zur verwendung davon
WO2011154007A1 (en) * 2010-06-08 2011-12-15 Leah Robert Bacteriophages for use against bacterial infections
EP3443970B1 (de) 2010-09-17 2020-09-09 Tecnifar-Indústria Técnica Farmacêutica, S.A. Antibakterielle phage, phagenpeptide und verfahren zu ihrer verwendung
RU2654596C2 (ru) * 2012-03-19 2018-05-21 Текнифар-Индустриа Текника Фармасеутика С.А. Композиции коктейля, содержащие антибактериальные фаги, и способы их применения
US10124027B2 (en) 2012-05-04 2018-11-13 Biocontrol Limited Therapeutic bacteriophage compositions
GB201402139D0 (en) 2014-02-07 2014-03-26 Fixed Phage Ltd Treatment of topical and systemic bacterial infections
WO2016066722A2 (en) * 2014-10-28 2016-05-06 Ian Humphery-Smith Bacteriophage combinations for human or animal therapy
CN110656093A (zh) * 2019-10-12 2020-01-07 山东省农业科学院畜牧兽医研究所 一种新型沙门氏菌噬菌体库及其应用
CN111826309A (zh) * 2020-06-30 2020-10-27 武汉合缘绿色生物股份有限公司 一种液体生物营养菌剂及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997039111A1 (en) * 1996-04-15 1997-10-23 Nymox Corporation Compositions containing bacteriophages and methods of using bacteriophages to treat infections
AU2001229342A1 (en) * 2000-01-11 2001-07-24 Intralytix, Inc. Method for produce sanitation using bacteriophages

Also Published As

Publication number Publication date
DK1504088T3 (da) 2007-12-17
EP1504088B1 (de) 2007-08-15
WO2003080823A2 (en) 2003-10-02
JP2005520545A (ja) 2005-07-14
ES2292996T3 (es) 2008-03-16
DE60315636T2 (de) 2008-05-08
CA2479897A1 (en) 2003-10-02
EP1504088A2 (de) 2005-02-09
DE60315636D1 (de) 2007-09-27
WO2003080823A3 (en) 2003-12-11
AU2003226499A1 (en) 2003-10-08
WO2003080823A8 (en) 2004-12-16
CN1643139A (zh) 2005-07-20

Similar Documents

Publication Publication Date Title
DE60315636D1 (de) Zur therapie und prophylaxe bakterieller infektionen geeignete bakteriophagen
Piewngam et al. Pathogen elimination by probiotic Bacillus via signalling interference
Khosravi et al. The prevalence of genes encoding leukocidins in Staphylococcus aureus strains resistant and sensitive to methicillin isolated from burn patients in Taleghani Hospital, Ahvaz, Iran
Uchiyama et al. DNase Sda1 allows invasive M1T1 Group A Streptococcus to prevent TLR9-dependent recognition
da Silva et al. Identification and in vitro antimicrobial susceptibility of Staphylococcus species isolated from goat mastitis in the Northeast of Brazil
Udobi et al. Prevalence and Antibiotic Resistance Pattern of Methicillin‐Resistant Staphylococcus aureus from an Orthopaedic Hospital in Nigeria
Rasheed et al. Discrepancies between phenotypic and genotypic identification methods of antibiotic resistant genes harboring Staphylococcus aureus
Nunes et al. Antimicrobial susceptibility of Portuguese isolates of Staphylococcus aureus and Staphylococcus epidermidis in subclinical bovine mastitis
Verma et al. Linezolid attenuates lethal lung damage during postinfluenza methicillin-resistant Staphylococcus aureus pneumonia
Månsson et al. Sequence types of Staphylococcus epidermidis associated with prosthetic joint infections are not present in the laminar airflow during prosthetic joint surgery
González-Olvera et al. Antibiotic resistance, virulence factors and genotyping of Pseudomonas aeruginosa in public hospitals of northeastern Mexico
Rehman et al. Prevalence and antibiotic susceptibility of clinical staphylococcus aureus isolates in various specimens collected from a tertiary care hospital, Hayatabad, Peshawar, Pakistan.: Antibiotic susceptibility of clinical staphylococcus aureus isolates in various specimens
Klotz et al. Possible risk for re-colonization with methicillin-resistant Staphylococcus aureus (MRSA) by faecal transmission
Adeoye-Isijola et al. Vancomycin intermediate resistant Staphylococcus aureus in the nasal cavity of asymptomatic individuals: a potential public health challenge
Pardo et al. Characteristics of Community‐Associated Methicillin‐Resistant Staphylococcus aureus (CA‐MRSA) Strains Isolated from Skin and Soft‐Tissue Infections in Uruguay
Moghaddam et al. Isolation and genetic characterization of vancomycin-resistant and mecC+ methicillin-resistant Staphylococcus aureus strains in clinical samples of Bojnurd, Northeastern Iran
Dai et al. Bactericidal and morphological effects of NE-2001, a novel synthetic agent directed against Helicobacter pylori
Riffat Prevalence, antibiotic susceptibility pattern and demographic factors related to methicillin resistant Staphylococcus aureus in Lahore, Pakistan
Mtsher et al. Estimation of erythromycin and inducible clindamycin resistance in Saphylococcus aureus isolated from clinical cases
Meenatchi et al. A narrative overview of Staphylococcus haemolyticus: resistance traits, virulence factors, and health impact
Kumar et al. Prevalence of MRSA and antimicrobial susceptibility Staphylococcus aureus in clinical samples in national capital region, India
Achmit et al. Antimicrobial resistance and detection of biofilm in Staphylococcus aureus isolates from Casablanca
Boukthir et al. A recurrent prosthetic joint infection caused by Erysipelothrix rhusiopathiae: case report and literature review
Apriliana et al. Resistance finding of Bacillus anthracis towards penicillin in east java, central java, and yogyakarta provinces, Indonesia
Wankhade et al. Study of antibiotic resistance profiling of Staphylococcus aureus isolated from clinical specimens of the patients attending a tertiary teaching hospital from Chhattisgarh

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties